153 related articles for article (PubMed ID: 12377651)
1. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer.
Gietema JA; Meinardi MT; Sleijfer DT; Hoekstra HJ; van der Graaf WT
Ann Oncol; 2002 Oct; 13(10):1616-20. PubMed ID: 12377651
[TBL] [Abstract][Full Text] [Related]
2. No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
De La Pena H; Sharma A; Glicksman C; Joseph J; Subesinghe M; Traill Z; Verrill C; Sullivan M; Redgwell J; Bataillard E; Pintus E; Dallas N; Gogbashian A; Tuthill M; Protheroe A; Hall M
Eur J Cancer; 2017 Oct; 84():354-359. PubMed ID: 28866371
[TBL] [Abstract][Full Text] [Related]
3. No role for routine chest radiography in stage I seminoma surveillance.
Tolan S; Vesprini D; Jewett MA; Warde PR; O'Malley M; Panzarella T; Sturgeon JF; Moore M; Tew-George B; Gospodarowicz MK; Chung PW
Eur Urol; 2010 Mar; 57(3):474-9. PubMed ID: 19577354
[TBL] [Abstract][Full Text] [Related]
4. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
5. Late relapse of germ cell tumors after cisplatin-based chemotherapy.
Gerl A; Clemm C; Schmeller N; Hentrich M; Lamerz R; Wilmanns W
Ann Oncol; 1997 Jan; 8(1):41-7. PubMed ID: 9093706
[TBL] [Abstract][Full Text] [Related]
6. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience.
Gels ME; Hoekstra HJ; Sleijfer DT; Marrink J; de Bruijn HW; Molenaar WM; Freling NJ; Droste JH; Schraffordt Koops H
J Clin Oncol; 1995 May; 13(5):1188-94. PubMed ID: 7537802
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
8. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.
Hartmann JT; Schmoll HJ; Kuczyk MA; Candelaria M; Bokemeyer C
Ann Oncol; 1997 Jun; 8(6):531-8. PubMed ID: 9261521
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for stage I non-seminomatous testicular cancer.
Abratt RP; Pontin AR; Barnes RD; Reddi BV
S Afr Med J; 1994 Sep; 84(9):605-7. PubMed ID: 7530863
[TBL] [Abstract][Full Text] [Related]
10. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.
Kollmannsberger C; Daneshmand S; So A; Chi KN; Murray N; Moore C; Hayes-Lattin B; Nichols C
J Clin Oncol; 2010 Feb; 28(4):537-42. PubMed ID: 20026807
[TBL] [Abstract][Full Text] [Related]
11. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.
Ernst DS; Brasher P; Venner PM; Czaykowski P; Moore MJ; Reyno L; Winquist E; Segal R; Hao D
Can J Urol; 2005 Apr; 12(2):2575-80. PubMed ID: 15877938
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
Pizzocaro G; Piva L; Salvioni R; Zanoni F; Milani A
Cancer; 1985 Nov; 56(10):2411-5. PubMed ID: 2412683
[TBL] [Abstract][Full Text] [Related]
13. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
14. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer.
Pizzocaro G; Salvioni R; Pasi M; Zanoni F; Milani A; Pilotti S; Monfardini S
Cancer; 1985 Jul; 56(2):249-55. PubMed ID: 2408728
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of testicular cancer: 10-year experience.
Ondrus D; Hornák M; Matoska J; Kausitz J; Belan V; Cársky S
Neoplasma; 1993; 40(4):247-53. PubMed ID: 7505886
[TBL] [Abstract][Full Text] [Related]
16. Non-seminomatous testicular germ cell tumours. Preliminary analysis of ongoing trials in the DATECA Study.
Rørth M; von der Maase H; Sandberg Nielsen E; Schultz HP; Svennekjaer IL
Acta Radiol Oncol; 1984; 23(4):295-304. PubMed ID: 6208750
[TBL] [Abstract][Full Text] [Related]
17. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.
Geldart TR; Gale J; McKendrick J; Kirby J; Mead G
BJU Int; 2006 Aug; 98(2):353-8. PubMed ID: 16879677
[TBL] [Abstract][Full Text] [Related]
18. Pattern of relapse after first line treatment of advanced stage germ-cell tumors.
Fléchon A; Culine S; Théodore C; Droz JP
Eur Urol; 2005 Dec; 48(6):957-63; discussion 963-4. PubMed ID: 16084010
[TBL] [Abstract][Full Text] [Related]
19. [In which marker-positive patients with germ cell tumors is residual tumor resection of value?].
Weinknecht S; Hartmann M; Weissbach L
Urologe A; 1998 Nov; 37(6):621-4. PubMed ID: 9887490
[TBL] [Abstract][Full Text] [Related]
20. Five-year survival of patients with disseminated nonseminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin.
Stoter G; Vendrik CP; Struyvenberg A; Sleyfer DT; Vriesendorp R; Schraffordt Koops H; van Oosterom AT; ten Bokkel Huinink WW; Pinedo HM
Cancer; 1984 Oct; 54(8):1521-4. PubMed ID: 6206937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
